PMC:6927068 / 18470-19447 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6927068","sourcedb":"PMC","sourceid":"6927068","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6927068","text":"Within the comparison between AAPADs and ADs alone, 14 trials42,44,46,47,49,52,53,57,59–62,65,66 reported the BP value before and after treatment. Even when we used a random-effect model, heterogeneity was too large (I2=82%), which might have been due to clinical heterogeneity or low methodological quality. Then, we tried to find the existence of this heterogeneity, and found that if we excluded four trials44,47,52,61 with outliers of larger BP value before treatment, the meta-analysis showed AAPADs had a better effect on reducing SBP than ADs alone (n=464 patients; MD, −5.06; 95% CI –6.76– −3.36, p\u003c0.00001; I2=32%) as well as DBP (n=464 patients; MD, −5.30; 95% CI –6.27– −4.33, p\u003c0.00001; I2=0%), which are shown in Figures 2 and 3. Twenty-one trials reported the efficacy rate, and the efficacy rate in the AAPAD group was significantly higher than that in the control group with ADs alone (RR, 1.22; 95% CI, 1.17–1.26; p\u003c0.00001; I2=0%), which is shown in Figure 4.","tracks":[]}